Microchip Assay for Serum Creatinine

血清肌酐的微芯片测定

• 批准号: 7157530
• 负责人: Dale M Willard
• 金额: $ 9.97万
• 依托单位: ADVANCED MICROLABS, LLC
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-30 至 2008-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7157530
• 关键词: biomedical equipment development; blood chemistry; capillary electrophoresis; clinical biomedical equipment; creatinine; diagnosis design /evaluation; diagnostic tests; electrochemistry; human tissue; kidney disorder diagnosis; kidney function; microprocessor /microchip; miniature biomedical equipment

DESCRIPTION (provided by applicant): Project Summary/Abstract: Currently, an estimated 8 million Americans have substantial kidney impairment and this number is growing. More people die annually from kidney failure than from either colon cancer, breast cancer, or prostate cancer. Estimated medical and other economic costs of chronic kidney disease are expected to approach $28 billion annually by 2010, with an additional $90 billion in annual costs related to increased cardiovascular disease, infections, and hospitalizations. The most commonly measured species for renal function assessment is creatinine, measured in blood serum (Scr). A variety of methods exist that allow for Scr determination. The least expensive variety rely on indirect detection: a reagent is added that specifically reacts with Scr to give an easily detected compound. Without exception, indirect methods suffer interferences from other specimen species resulting in less confident assessments. Direct detection of Scr is possible, but requires expensive and complicated instrumentation, such as, High Performance Liquid Chromatography (HPLC). Advanced MicroLabs, LLC (AML) is dedicated to the development of our unique Microchip Capillary Electrophoresis with Electrochemical Detection (Microchip CE-EC) technology for tomorrow's monitoring devices. Our device will be capable of measuring hundreds of assays on a single, disposable chip about the size of a matchbook. Analysis will be quick (ca. 3 min) and inexpensive. The device will be user-friendly, operate in a point of care or clinical situation. Most importantly, because our device detects Scr directly, it will suffer little interference. While this proposal focuses on a Scr assay, our system is amendable to simultaneous determination of multiple renal disease markers. Phase I results will establish a sampling protocol for Microchip CE-EC detection of Scr starting with a whole blood sample. Using dilutions, filtering, and chromatography, Scr will be uniquely detected. In Phase II, all procedures will be combined into a self-contained, integrated, microchip format. Project Narrative: Currently, an estimated 8 million Americans have substantial kidney impairment and this number is growing. Our proposed medical device will allow medical practitioners to diagnose kidney impairment faster, more accurately, more reliably, and less intrusively.

描述（由申请人提供）：项目摘要/摘要：目前，估计有800万美国人的肾脏障碍大大，而且这一数字正在增长。每年死于肾脏衰竭的人比结肠癌，乳腺癌或前列腺癌多。预计到2010年，慢性肾脏疾病的估计医疗和其他经济成本预计将每年280亿美元接近280亿美元，每年额外的900亿美元成本与心血管疾病，感染和住院治疗增加有关。用于肾功能评估的最常见的物种是肌酐，在血清（SCR）中测量。存在各种允许SCR确定的方法。最便宜的品种依赖于间接检测：添加了一种试剂，该试剂与SCR有特殊反应以提供易于检测的化合物。毫无例外，间接方法会遭受其他标本物种的干扰，导致评估不太自信。直接检测SCR是可能的，但需要昂贵且复杂的仪器，例如高性能液相色谱法（HPLC）。 Advanced Microlabs，LLC（AML）致力于使用电化学检测（Microchip CE-EC）技术开发我们独特的微芯片毛细管电泳，用于明天的监测设备。我们的设备将能够测量一个关于火柴手册大小的一次性芯片上的数百种测定。分析将是快速（约3分钟）和便宜的。该设备将在用户友好，在护理或临床情况下运行。最重要的是，由于我们的设备直接检测到SCR，因此几乎不会受到干扰。尽管该提案侧重于SC​​R分析，但我们的系统可以同时确定多种肾脏疾病标记。第一阶段的结果将建立一种以全血样本开头的微芯片CE-EC检测SCR检测的抽样方案。使用稀释，过滤和色谱法，将独特地检测到SCR。在第二阶段，所有程序都将合并为独立的，集成的，微芯片的格式。项目叙述：目前，估计有800万美国人的肾脏障碍很大，而且这一数字正在增长。我们提出的医疗设备将使医生能够更快，更准确，更可靠，更省力地诊断肾脏损伤。